- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 17.04. | Canaan hires Pfizer executive, reels in $100M for biotech investing | ||
| 16.04. | J&J sees mixed performance from new multiple myeloma drugs | ||
| 16.04. | Intra-Cellular builds case for depression drug with late-stage trial win | ||
| 16.04. | Cullinan Oncology changes name, pivots to autoimmune disease | ||
| 16.04. | Biotech landlord Alexandria on research clusters and the sector's recovery | ||
| 15.04. | Roche reports survival data for new dual-acting lymphoma drug | ||
| 15.04. | Neumora's schizophrenia drug hit with clinical hold | ||
| 15.04. | Regeneron commits $500M to new venture capital fund | ||
| 15.04. | Ultragenyx says Angelman therapy is working, but safety questions remain | ||
| 15.04. | The growing role for cfHPV-DNA testing in OPSCC therapeutic development | ||
| 15.04. | Keeping cleanrooms clean: Choosing the right laboratory equipment is key | ||
| 12.04. | European regulator concludes no suicide link to obesity drugs | ||
| 12.04. | Roche, Adaptimmune part ways on cell therapy research | ||
| 12.04. | Biotech IPOs bounced back in first quarter, but backlog remains | ||
| 11.04. | Century buys a startup, raises funding in cell therapy expansion | ||
| 11.04. | US sues Regeneron, alleging false price reporting on Eylea | ||
| 10.04. | Vertex to buy kidney disease drugmaker Alpine for $4.9B | ||
| 10.04. | J&J, Rallybio partner on drug development for rare fetal condition | ||
| 10.04. | Novartis pauses some trials of cancer drug Kisqali to fix manufacturing | ||
| 10.04. | New postpartum depression drugs are here. Diagnosis, treatment hurdles still stand in the way. | ||
| 09.04. | PureTech launches Seaport, hoping to create Karuna 2.0 | ||
| 09.04. | Pfizer, with new study results, seeks to bring RSV shot to adults aged 18-59 | ||
| 08.04. | Private biotech funding ticks up as venture firms deploy cash | ||
| 08.04. | Trial shows Wegovy can ease heart failure symptoms | ||
| 08.04. | Women want to participate in clinical trials. Lack of flexibility is still a problem. |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und
